In cisplatin-ineligible patients with muscle-invasive bladder cancer, enfortumab vedotin–pembrolizumab plus surgery led to better event-free survival (74.7%, vs. 39.4%) and overall survival (79.7%, vs. 63.1%) than surgery alone at 2 years.
Hematology/Oncology
|11th Mar, 2026
|The New England Journal of Medicine
Hematology/Oncology
|11th Mar, 2026
|The New England Journal of Medicine
Hematology/Oncology
|11th Mar, 2026
|The New England Journal of Medicine
Hematology/Oncology
|11th Mar, 2026
|The New England Journal of Medicine
Hematology/Oncology
|11th Mar, 2026
|The New England Journal of Medicine
Hematology/Oncology
|11th Mar, 2026
|The New England Journal of Medicine
Hematology/Oncology
|11th Mar, 2026
|The New England Journal of Medicine